单克隆抗体在糖尿病中的应用:从2004年到2024年的文献分析分析
Rui Wei1, Bochao Jia2, Shuang Zheng1
1Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Human vaccines & immunotherapeutics
|July 28, 2025
概括
单克隆抗体 (mAbs) 显示出糖尿病治疗的前景. 本文献分析揭示了主要的研究趋势和重点,特别是1型糖尿病 (T1D) 和2型糖尿病 (T2D) 管理.
科学领域:
- 免疫学和内分泌学.
- 生物技术和制药科学 生物技术和制药科学
背景情况:
- 单克隆抗体 (mAbs) 是糖尿病的重要治疗途径,利用免疫生物机制.
- 了解糖尿病的mAb研究的不断变化的格局对于未来的治疗开发至关重要.
研究的目的:
- 从2004年到2024年对糖尿病治疗单克隆抗体的全球研究进行文献分析.
- 确定关键的研究重点,趋势和该领域的主要贡献者.
- 评估mAbs在1型糖尿病 (T1D) 和2型糖尿病 (T2D) 管理中的当前状态和未来潜力.
主要方法:
- 从Web of Science核心集合 (2004-2024) 中对文献数据进行图书统计分析.
- 使用R软件和VOSviewer进行全面的数据分析.
- 确定了出版趋势,引用频率,领先的国家,机构和作者,以及关键的研究主题.
主要成果:
- 共有900篇论文发表,活动在2019年达到顶峰,随后是稳定的开发阶段.
- 美国在出版物,引用和合作方面处于领先地位;糖尿病杂志的产量最高.
- 确定了T1D的四个主要研究重点:临床试验,动物模型,免疫耐受性诱导和安全性/有效性评估.
- 对于T1D mAbs,临床进展显著,而T2D策略在很大程度上是临床前的,但有前途的.
结论:
- 对糖尿病的单克隆抗体研究是一个充满活力的领域,在T1D方面取得了进展,在T2D方面也有新兴的潜力.
- 未来的进步在于组合疗法,个性化医学和更深入的机制研究,以提高mAb的安全性和有效性.
- 这一分析为指导基于mAb的糖尿病管理的未来研究和开发提供了关键的见解.
关键词:
单克隆抗体是一种单克隆抗体.圣经计量资料 (Bibliometric bibliometric bibliometric) 是指参考书目中的资料.糖尿病 糖尿病患者 糖尿病患者研究重点研究重点研究重点视觉化的可视化更多相关视频
09:45Production of Monoclonal Antibodies Targeting Aminopeptidase N in the Porcine Intestinal Mucosal Epithelium
Published on: May 18, 2021
2.1K
06:50A High-Throughput Electrochemiluminescence 7-Plex Assay Simultaneously Screening for Type 1 Diabetes and Multiple Autoimmune Diseases
Published on: May 29, 2020
2.7K
相关概念视频
Hybridoma Technology
15.3K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
15.3K
Diabetes Mellitus: Overview and Type I Subtype
3.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
3.3K
Diabetes: Management and Pharmacotherapy
393
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
393
